Health Care • Medical Specialities
$3.86 ▼ -0.07
(-1.78%)
MKT CAP: $237.7M • VOL: 113.9K
52W L $2 52W H $8
ROARABLE / RQD
E • 34/100
PIOTROSKI
4 / 9
TLSI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $45.2M | $29.4M | $18.5M |
| YoY Revenue Growth % | +53.4% | +59.0% | — |
| Gross Profit | $38.2M | $25.3M | — |
| Gross Margin % | 84.6% | 86.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$26.9M | -$36.2M | -$54.5M |
| Operating Margin % | -59.7% | -80.0% | -80.0% |
| Net Income (GAAP) | -$39.2M | -$30.0M | -$59.4M |
| EBITDA (Normalized) | -$26.2M | -$35.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.0M | -$40.8M | -$50.6M |
| Capital Expenditures (CapEx) | $918.0K | $345.0K | — |
| Free Cash Flow (FCF) | -$18.9M | -$41.2M | -$50.6M |
| FCF Margin % | -41.9% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.4M | $8.5M | — |
| Total Debt (Short + Long Term) | $33.0M | $22.1M | — |
| Total Stockholders' Equity | -$33.9M | -$25.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TLSI.